OncoMatch/Clinical Trials/NCT05086692
A Beta-only IL-2 ImmunoTherapY Study
Is NCT05086692 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including MDNA11 and Pembrolizumab (KEYTRUDA®) for advanced solid tumor.
Treatment: MDNA11 · Pembrolizumab (KEYTRUDA®) — This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Renal Cell Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Gastric Cancer
Cervical Cancer
Urothelial Carcinoma
Head and Neck Squamous Cell Carcinoma
Mesothelioma
Esophageal Carcinoma
Endometrial Cancer
Ovarian Cancer
Melanoma
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer therapy
Prior systemic anti-cancer therapy including investigational agents within 4 weeks (could consider shorter interval for kinase inhibitors or other short half-life drugs) prior to start of treatment.
Cannot have received: radiotherapy
Exception: 1-week washout for palliative radiation (<2 weeks of radiotherapy) to non-CNS disease
Prior radiotherapy within 2 weeks prior to start of treatment or has had a history of radiation pneumonitis. A 1-week washout is required for palliative radiation (<2 weeks of radiotherapy) to non-CNS disease.
Cannot have received: radiation therapy to the lung > 30Gy
Radiation therapy to the lung that is > 30Gy within 6 months prior to start of treatment.
Cannot have received: investigational agent/device
Exception: concomitant participation in an observational study must be discussed on a case-by-case basis with the MM for approval
Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to start of treatment.
Lab requirements
Blood counts
Demonstrated adequate organ function
Kidney function
Demonstrated adequate organ function
Liver function
Demonstrated adequate organ function
Demonstrated adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sharp Memorial Hospital · San Diego, California
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- Providence Saint John's Health Center · Santa Monica, California
- Boca Raton Regional Hospital · Boca Raton, Florida
- Emory - Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify